54629-13-9

Basic information

• Product Name: 2-(4-FLUOROPHENOXY)NICOTINIC ACID
• Synonyms: BUTTPARK 96\14-48;2-(4-FLUOROPHENOXY)NICOTINIC ACID;2-(4-FLUOROPHENOXY)PYRIDINE-3-CARBOXYLIC ACID;2-(4-Fluorophenoxy)-Nicotinic;2-(4-Fluorophenoxy)nicotinic acid 97%;2-(4-Fluorophenoxy)pyridine-3-carboxylic acid, 3-Carboxy-2-(4-fluorophenoxy)pyridine, 1-[(3-Carboxypyridin-2-yl)oxy]-4-fluorobenzene
• CAS NO: 54629-13-9
• Molecular Formula: C₁₂H₈FNO₃
• Molecular Weight: 233.2
• Mol File: 54629-13-9.mol
• Article Data: 5

Chemical Properties

• Melting Point: 187 °C
• Boiling Point: 365.2 °C at 760 mmHg
• Flash Point: 174.7 °C
• Appearance: /
• Density: 1.371 g/cm³
• Vapor Pressure: 5.63E-06mmHg at 25°C
• PKA: 2.21±0.36(Predicted)
• CAS DataBase Reference: 2-(4-FLUOROPHENOXY)NICOTINIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-FLUOROPHENOXY)NICOTINIC ACID(54629-13-9)
• EPA Substance Registry System: 2-(4-FLUOROPHENOXY)NICOTINIC ACID(54629-13-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 54629-13-9(Hazardous Substances Data)

Usage

General Description

2-(4-fluorophenoxy)nicotinic acid is a chemical compound with the molecular formula C12H8FNO3. It is a derivative of nicotinic acid, also known as niacin, and contains a fluorine atom attached to a phenyl group. 2-(4-FLUOROPHENOXY)NICOTINIC ACID is used in pharmaceutical research as a potential drug target for conditions such as diabetes and cardiovascular disease. It is also being studied for its potential anti-inflammatory and immune-modulating properties. 2-(4-fluorophenoxy)nicotinic acid is not currently used in any commercial products, but its unique structure and potential therapeutic applications make it an area of interest in the field of medicinal chemistry.

InChI:InChI=1/C12H8FNO3/c13-8-3-5-9(6-4-8)17-11-10(12(15)16)2-1-7-14-11/h1-7H,(H,15,16)/p-1

Upstream product

• 771553-62-9 2-(4-fluoro-phenoxy)-nicotinic acid ethyl ester 
• 371-41-5 4-Fluorophenol 
• 1452-94-4 ethyl 2-chloronicotinate 
• 2942-59-8 2-chloronicotinic acid 

Downstream Products

• 214756-98-6 2-(4-Fluoro-phenoxy)-N-(5-methyl-pyrazin-2-ylmethyl)-nicotinamide 
• 214757-87-6 2-(4-Fluoro-phenoxy)-N-[4-(1-hydroxy-1-methyl-ethyl)-cyclohex-1-enylmethyl]-nicotinamide 
• 214757-07-0 2-(4-Fluoro-phenoxy)-N-(5-oxo-morpholin-2-ylmethyl)-nicotinamide 
• 214754-72-0 2-(4-Fluoro-phenoxy)-N-thiophen-2-ylmethyl-nicotinamide 
• 214755-31-4 N-(5-Chloro-thiophen-2-ylmethyl)-2-(4-fluoro-phenoxy)-nicotinamide 
• 214756-78-2 2-(4-Fluoro-phenoxy)-N-(4-sulfamoyl-benzyl)-nicotinamide 
• 214758-15-3 N-[2-Fluoro-4-(1-hydroxy-1-methyl-ethyl)-benzyl]-2-(4-fluoro-phenoxy)-nicotinamide 
• 581772-23-8 [4-({[2-(4-fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester 
• 1227852-04-1 N'-(4-aminobenzoyl)-2-(4-fluorophenoxy)nicotinohydrazide 

Relevant articles and documents

A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function

Nicotinamide (2) is a potent and selective inhibitor of the PDE4D isozyme and as a chemical tool selectively blocks eosinophil mediator release and chemotaxis thus linking the role of PDE4D to eosinophil function.

Discovery of a new class of glucosylceramide synthase inhibitors

A novel series of potent inhibitors of glucosylceramide synthase are described. The optimization of biochemical and cellular potency as well as ADME properties led to compound 23c. Broad tissue distribution was obtained following oral administration to mice. Thus 23c could be another useful tool compound for studying the effects of GCS inhibition in vitro and in vivo.

Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula: wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2;n is 1 or 2; A is is selected from the partial Formulas: where q is 1, 2, or 3, W3 is -O-; -N(R9)-; or -OC(=O)-; R7 is selected from -H; -(C1-C6)alkyl, -(C2-C6)alkenyl, or -(C2-C6)alkynyl substituted by 0 to 3 substituents R10; -(CH2)u-(C3-C7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R10; and phenyl or benzyl substituted by 0 to 3 R14; R8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is ―O―; ―S(=O)t―, where t is 0, 1, or 2; or -N(R3)―; Y is C(R1a)―, or -[N□(O)k] where k is 0 or 1; R4, R5 and R6 are (1)―H; provided that R5 and R6 are not both -H at the same time, ―F; ―Cl; -(C2-C4) alkynyl; -R16; ―OR16; -S(=O)pR16; ―C(=O)R16, -C(=O)OR16; -OC(=O)R16; -CN; -NO2; -C(=O)NR16R17; -OC(=O)NR16R17; ―NR12aC(=O)NR16R17; -NR12aC(=NR12)NR16R17; -NR12aC(=NCN)NR15R16; -NR12aC(=N-NO2)NR15R16; -C(=NR12a)NR15R16; -CH2C(=NR12a)NR16R17; ―OC(=NR12a)NR16R17; ―OC(=N―NO2)NR16R17; -NR16R17; -CH2NR16R17; -NR12aC(=O)R16; -NR12aC(=O)OR16; =NOR16; ―NR12aS(=O)pR17 -S(=O)pNR16R17; and ―CH2C(=NR12a)NR16R17;(2) -(C1-C4) alkyl including dimethyl and -(C1-C4) alkoxy substituted with 0 to 3 substituents ―F or ―Cl; or 0 or 1 substituent (C1-C2) alkoxycarbonyl―, (C1-C2) alkylcarbonyl―, or (C1-C2) alkylcarbonyloxy―; or (3) an aryl or heterocyclic moiety; or (4) R5 and R6 are taken together to form a moiety of partial Formulas (1.3.1) through (1.3.15):B1 and B2 is a moiety comprising a saturated or unsaturated carbon ring system that is 3- to 7-membered monocyclic, or that is 7- to 12-membered, fused or discontinuous, polycyclic; wherein optionally one carbon atom thereof may be replaced by a heteroatom selected from N, O and S; and where N is selected, optionally a second carbon atom thereof may be replaced by a heteroatom selected from N, O, or S; or a pharmaceutically acceptable salt thereof.